FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
Inclusion Criteria:
Exclusion Criteria:
Salem, Virginia 24153, United States
Aleksandur Stamboliyski, Plovdiv 4004, Bulgaria
Budinova, Prague 180 00, Czechia
Cedex, Cedex 54100, France
Eric Tabarly, Nantes 44202, France
Woehrendamm, Schleswig-Holstein 22927, Germany
Crete, Crete 71110, Greece
Mezourlo, Larissa 411 10, Greece
Csabai Kapu, Miskolc 3529, Hungary
Nyiregyháza, Nyiregyháza 4412, Hungary
Seregelyesi, Szekesfehervar 8000, Hungary
Vishakhapattanam, Andhhra Pradesh 530002, India
Hyderabad, Andhra Pradesh 500033, India
Hyderabad, Andhra Pradesh 500034, India
Negeri Sembilan, Darul Khusus 71800, Malaysia
Str. Republicii Nr. 34-36, Cluj-Napoca 400015, Romania
Saint Petersburg, Sankt-Peterburg 197022, Russia
Dagomysskaya Str., Sochi 354057, Russia
Hospital Drive, Singapore 169610, Singapore
Mount Elizabeth, Singapore 258500, Singapore
Napier Road, Singapore 258500, Singapore
Hwasun Up, Chonnam 519-809, South Korea
Ilsandong-gu, Goyang 411-769, South Korea
Gangnam-Gu, Seoul 135-710, South Korea
Jongno-gu, Seoul 110-744, South Korea
Seongbuk-gu, Seoul 136-705, South Korea
Songpa-gu, Seoul 138-736, South Korea
Paldal-gu, Suwon Gyeonggi-do 442-723, South Korea
Taipei, Taipei 112, Taiwan
Toayuan, Toayuan 333, Taiwan
Cottingham Hull, Hull HU16 5JQ, United Kingdom
Wythenshawe, Manchester M23 9LT, United Kingdom